Thorne HealthTech Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Paul Jacobson

Algemeen directeur

US$4.1m

Totale compensatie

Percentage CEO-salaris	13.0%
Dienstverband CEO	13.8yrs
Eigendom CEO	n/a
Management gemiddelde ambtstermijn	9.8yrs
Gemiddelde ambtstermijn bestuur	8.4yrs

Recente managementupdates

Recent updates

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

Aug 12

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Aug 09

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Jun 05

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Mar 23

Thorne HealthTech: Good Potential At A Low Price

Jan 11

Analyse CEO-vergoeding

Hoe is Paul Jacobson's beloning veranderd ten opzichte van Thorne HealthTech's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2023	n/a	n/a	US$20m
Mar 31 2023	n/a	n/a	US$10m
Dec 31 2022	US$4m	US$530k	US$16m
Sep 30 2022	n/a	n/a	US$6m
Jun 30 2022	n/a	n/a	US$3m
Mar 31 2022	n/a	n/a	US$9m
Dec 31 2021	US$13m	US$530k	US$4m
Sep 30 2021	n/a	n/a	-US$822k
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$3m
Dec 31 2020	US$759k	US$530k	-US$3m

Compensatie versus markt: De totale vergoeding ($USD 4.09M ) Paul } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 2.40M ).

Compensatie versus inkomsten: De vergoeding van Paul is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Paul Jacobson (68 yo)

13.8yrs

Tenure

US$4,088,000

Compensatie

Mr. Paul F. Jacobson Co-Founded Thorne HealthTech, Inc. in 2010 and has been its Chief Executive Officer and Director since 2010. He is Chairman of Thorne HealthTech, Inc. He was Interim Principal Financi...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Jacobson	Co-Founder	13.8yrs	US$4.09m	geen gegevens
William McCamy	President	no data	US$1.35m	geen gegevens
Saloni Varma	CFO & Director	less than a year	US$463.20k	0.032% $ 173.4k
Thomas McKenna	COO & Director	13.8yrs	US$2.89m	geen gegevens
Scott Hurth	Chief Technology Officer	9.8yrs	geen gegevens	geen gegevens
Nathan Price	Chief Scientific Officer & CEO of Onegevity	no data	geen gegevens	geen gegevens
Thomas Wilson	VP & Head of Investor Relations	no data	geen gegevens	geen gegevens
Kim Pearson	General Counsel	28.8yrs	geen gegevens	geen gegevens
Michelle Crow	Chief Marketing Officer	5.9yrs	geen gegevens	geen gegevens
Rob Monteleone	Senior VP of Professional Sales	no data	geen gegevens	geen gegevens
Bodi Zhang	Chief Strategy Officer	no data	geen gegevens	geen gegevens
Stephen Phipps	Chief Innovation Officer	2.8yrs	geen gegevens	geen gegevens

9.8yrs

Gemiddelde duur

45.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van THRN is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Paul Jacobson	Co-Founder	13.8yrs	US$4.09m	geen gegevens
Saloni Varma	CFO & Director	2.1yrs	US$463.20k	0.032% $ 173.4k
Thomas McKenna	COO & Director	13.8yrs	US$2.89m	geen gegevens
Riccardo Braglia	Independent Director	11.8yrs	geen gegevens	0% $ 0
Sarah Kauss	Independent Director	2.1yrs	US$469.45k	0.021% $ 114.6k
Toshitaka Inuzuka	Independent Director	5yrs	geen gegevens	0% $ 0

8.4yrs

Gemiddelde duur

58.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van THRN wordt beschouwd als ervaren (gemiddelde ambtstermijn 8.4 jaar).

Thorne HealthTech Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Thorne HealthTech, Inc. Announces Executive Changes

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Recent updates

Thorne Appoints Mary Beech as Chief Growth Officer

Thorne Healthtech, Inc. Files Form 15

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from NASDAQ Composite Index

Thorne HealthTech's Common Stock To Be Delisted from Nasdaq Global Select Market

Thorne HealthTech Receives Non-Compliance Notice from Nasdaq

Price target increased by 11% to US$8.36

Thorne Healthtech, Inc. Announces Resignation of Takeshi Minakata from the Board of Directors

Investor sentiment improves as stock rises 27%

Results: Thorne HealthTech, Inc. Beat Earnings Expectations And Analysts Now Have New Forecasts

New minor risk - Shareholder dilution

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Thorne Healthtech, Inc. Provides Earnings Guidance for 2023

Thorne HealthTech, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Price target increased by 8.7% to US$7.50

Thorne HealthTech Reportedly Working with Bank to Explore Sale

Investor sentiment improves as stock rises 17%

Thorne HealthTech, Inc. (NASDAQ:THRN) Not Flying Under The Radar

First quarter 2023 earnings: EPS misses analyst expectations

Thorne HealthTech, Inc. Reaffirms Financial Guidance for the Full-Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. (NasdaqGS:THRN) acquired PreCon Health, Inc. from Eigenlyfe LLC for $5 million.

Investor sentiment improves as stock rises 15%

Thorne HealthTech, Inc. Announces Executive Changes

Investors Will Want Thorne HealthTech's (NASDAQ:THRN) Growth In ROCE To Persist

Investor sentiment improved over the past week

Thorne Healthtech's OneDraw Device Used in Department of Defense's Cancer Moonshot 2.0 Project, Prometheus, as Part of President Biden Initiative

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Price target decreased to US$7.50

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Net Sales Guidance for the Full Year 2022

Thorne HealthTech, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Thorne HealthTech Grows But Faces Macro Headwinds

Thorne Healthtech's OneDraw(TM) Blood Collection Device Receives PMDA Certification in Japan

Thorne HealthTech's blood collection device OneDraw gets clearance in Japan

Consensus forecasts updated

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Thorne HealthTech, Inc. Revises Sales Guidance for the Full-Year 2022

Thorne HealthTech swings to Q2 Non-GAAP loss per share, revenue down Y/Y, FY22 guidance revised

Investor sentiment improved over the past week

Thorne HealthTech, Inc. Achieves Self-Affirmed GRAS Status for Nicotinamide Riboside Malate Product

Thorne HealthTech, Inc.(NasdaqGS:THRN) dropped from Russell 2500 Value Index

Thorne HealthTech: Poised To Outperform Other Nutraceutical Companies

Thorne HealthTech, Inc. Relaunches Gut Health Test

Thorne HealthTech, Inc. Relaunches Gut Health Test

First quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Thorne HealthTech, Inc. Reaffirms Sales Guidance for the Full-Year 2022

Thorne HealthTech, Inc., Annual General Meeting, Jun 02, 2022

Co-Founder exercised options to buy US$326k worth of stock.

Consensus forecasts updated

Shareholders Can Be Confident That Thorne HealthTech's (NASDAQ:THRN) Earnings Are High Quality

Full year 2021 earnings: EPS misses analyst expectations

Thorne HealthTech: Good Potential At A Low Price

Forecast breakeven date pushed back to 2022

Forecast to breakeven in 2021

Thorne HealthTech, Inc. has completed an IPO in the amount of $70 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd